<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543035</url>
  </required_header>
  <id_info>
    <org_study_id>ETRALL DR3215</org_study_id>
    <nct_id>NCT01543035</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs</brief_title>
  <acronym>ETRALL</acronym>
  <official_title>Phase III Prospective Multicentric Trial Evaluating Etravirine for HIV Infected Patients in Need of Lipid Lowering Drugs: the ETRALL Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calmy Alexandra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag A.G., Switzerland</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dyslipidaemia, characterized by raised triglyceride and low-density lipoprotein (LDL)
      cholesterol and reduced high-density lipoprotein (HDL) cholesterol levels, is common in
      HIV-infected individuals, and has been associated with HIV infection itself and
      antiretroviral therapy (ART). These abnormalities are well-established markers of
      cardiovascular (CVD) risk in the general population. Studies have suggested an increased risk
      of CVD associated with ART exposure over and above that conveyed by traditional
      cardiovascular risk factors. In HIV population to reduce lipid parameters, the most usual
      clinical strategy remains to add a statin treatment.

      Recent studies suggested ART switch can represent an interesting alternative to statins to
      reduce lipid plasma levels.

      The purpose of this study is to evaluate the frequency with which the replacement of LPV/r
      (lopinavir/ritonavir), ATZ/r (atazanavir/ritonavir), DRV/r (darunavir/ritonavir) or EFV
      (efavirenz) by ETR (Etravirin) in dyslipidemic patients with suppressed viremia would obviate
      the necessity to administer statins.

      A prospective, phase III study in which the statin treatment of dyslipidemic HIV patients on
      antiretroviral drugs (ARVs) will be interrupted during 4 weeks is proposed.

      At week 4, patients qualifying for a lipid lowering drug (calculated LDL-C≥ 3mmol/L) will
      replace EFV, LPV/r, DRV/r or ATZ/r by ETR. The proportion of patients not qualifying anymore
      for a statin treatment at 12 weeks (i.e. after 8 weeks of ETR treatment) will be determined.
      Additionally, the lipid level changes will be assessed at 12 weeks. Inflammatory markers will
      be measured at baseline, at drug switch and at the end of the study

      Study drug will be provided by the drug manufacturer (Janssen-Cilag, AG). Compliance for
      study drug will be done at week-4 and week-12, Returned study medication will be counted and
      the amount notified on the Case Report Form (CRF).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients not qualifying anymore for statin treatment</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting lipids changes</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Etravirine switch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in need of lipid-lowering drug switched from boosted PI or EFV to Etravirine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>stop statin and switch to an antiretroviral drug with less impact on lipid metabolism</intervention_name>
    <description>Switch from a boosted PI or efavirenz based ART regimen to etravirine 400 mg/day once daily for patients in need of lipid lowering drugs (statin) after one month wash out of statin</description>
    <arm_group_label>Etravirine switch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  On statin treatment for at least 3 months (fluvastatin, simvastatin, pravastatin,
             rosuvastatin, or atorvastatin) for primary prevention of cardiovascular disease

          -  HIV Ribonucleic Acid (RNA) below 50 copies/mL, minimum duration 3 months

          -  On a stable (&gt; 3 months) ARV treatment including at least one of the following drugs:
             LPV/r, ATZ/r, DRV/r, or EFV

          -  No previous virological escape or virological escape documented with a genotype at the
             time of failure only showing a K103M mutation.

        Exclusion Criteria:

          -  Probability of cardiovascular complications of &gt; 20% according to the Swiss GSLA
             (&quot;Groupe de travail Lipide et Athérosclérose&quot;/Swiss Atherosclerosis Association)
             guidelines

          -  Previous cardiovascular disease (including stroke)

          -  Known diabetes

          -  Known intolerance of ETR

          -  Presence of a documented drug mutation (excluding the K103M)

          -  Regimen including non-boosted ATZ

          -  Known hyperlipidemia before ARV initiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Calmy Alexandra, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geneva University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsspital Basel Klinik für Infektiologie &amp; Spitalhygiene</name>
      <address>
        <city>Bale</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital PKT2B / Poliklinik für Infektiologie</name>
      <address>
        <city>Berne</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUG /Division des Maladies infectieuses Unité VIH/SIDA</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Neuchâtelois - La Chaux-de-Fonds Service des Maladies infectieuses</name>
      <address>
        <city>La Chaux-de-Fonds</city>
        <zip>2300</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV / Service des maladies infectieuses Médecine 2</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital / Infektiologie und Spitalhygiene Departement Innere Medizin</name>
      <address>
        <city>St Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich Division of Infectious Diseases and Hospital Epidemiology Department of Internal Medicine</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Riddler SA, Li X, Chu H, Kingsley LA, Dobs A, Evans R, Palella F, Visscher B, Chmiel JS, Sharrett A. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med. 2007 Jul;8(5):280-7.</citation>
    <PMID>17561873</PMID>
  </reference>
  <reference>
    <citation>Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992 May;74(5):1045-52.</citation>
    <PMID>1373735</PMID>
  </reference>
  <reference>
    <citation>Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsley LA. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003 Jun 11;289(22):2978-82.</citation>
    <PMID>12799406</PMID>
  </reference>
  <reference>
    <citation>Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998 May 7;12(7):F51-8.</citation>
    <PMID>9619798</PMID>
  </reference>
  <reference>
    <citation>Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC, Schambelan M. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000 Jan 1;23(1):35-43.</citation>
    <PMID>10708054</PMID>
  </reference>
  <reference>
    <citation>Thiébaut R, Daucourt V, Mercié P, Ekouévi DK, Malvy D, Morlat P, Dupon M, Neau D, Farbos S, Marimoutou C, Dabis F. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine. Clin Infect Dis. 2000 Dec;31(6):1482-7. Epub 2000 Nov 29.</citation>
    <PMID>11096016</PMID>
  </reference>
  <reference>
    <citation>Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S; INITIO Trial International Coordinating Committee. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS. 2007 Nov 30;21(18):2445-53.</citation>
    <PMID>18025881</PMID>
  </reference>
  <reference>
    <citation>Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003 Nov 20;349(21):1993-2003. Erratum in: N Engl J Med. 2004 Feb 26;350(9):955.</citation>
    <PMID>14627784</PMID>
  </reference>
  <reference>
    <citation>DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte Ad, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007 Apr 26;356(17):1723-35.</citation>
    <PMID>17460226</PMID>
  </reference>
  <reference>
    <citation>Carey D, Amin J, Boyd M, Petoumenos K, Emery S. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010 Sep;65(9):1878-88. doi: 10.1093/jac/dkq231. Epub 2010 Jun 16. Review.</citation>
    <PMID>20554568</PMID>
  </reference>
  <reference>
    <citation>Sension M, Andrade Neto JL, Grinsztejn B, Molina JM, Zavala I, González-García J, Donnelly A, Phiri P, Ledesma E, McGrath D; 067 Study Group. Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):153-62. doi: 10.1097/QAI.0b013e3181a5701c.</citation>
    <PMID>19346966</PMID>
  </reference>
  <reference>
    <citation>Nguyen A, Calmy A, Delhumeau C, Mercier IK, Cavassini M, Fayet-Mello A, Elzi L, Genné D, Rauch A, Bernasconi E, Hirschel B; Swiss HIV Cohort Study. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS. 2011 Jan 2;25(1):57-63. doi: 10.1097/QAD.0b013e32833f9f63. Erratum in: AIDS. 2011 Mar 13;25(5):729. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.</citation>
    <PMID>21076278</PMID>
  </reference>
  <reference>
    <citation>Ruxrungtham K, Pedro RJ, Latiff GH, Conradie F, Domingo P, Lupo S, Pumpradit W, Vingerhoets JH, Peeters M, Peeters I, Kakuda TN, De Smedt G, Woodfall B; TMC125-C227 study group. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med. 2008 Nov;9(10):883-96. doi: 10.1111/j.1468-1293.2008.00644.x. Epub 2008 Sep 14.</citation>
    <PMID>18795960</PMID>
  </reference>
  <reference>
    <citation>Spencer FA, Allegrone J, Goldberg RJ, Gore JM, Fox KA, Granger CB, Mehta RH, Brieger D; GRACE Investigators. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med. 2004 Jun 1;140(11):857-66.</citation>
    <PMID>15172899</PMID>
  </reference>
  <reference>
    <citation>McGowan MP; Treating to New Target (TNT) Study Group. There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation. 2004 Oct 19;110(16):2333-5. Epub 2004 Oct 11.</citation>
    <PMID>15477411</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Calmy Alexandra</investigator_full_name>
    <investigator_title>MD, PhD, HIV department Director</investigator_title>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>lipid lowering drugs</keyword>
  <keyword>etravirine</keyword>
  <keyword>patient</keyword>
  <keyword>statin treatment</keyword>
  <keyword>EFV or boosted PI antiretroviral treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Etravirine</mesh_term>
    <mesh_term>Hypolipidemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

